公开(公告)号：US12188097B2

公开(公告)日：2025-01-07

申请号：US18330112

申请日：2023-06-06

Applicant: Astellas Pharma Inc. ,  TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH

Inventor： Ugur Sahin ,  Ozlem Tureci ,  Daniel Maurus

IPC: C12Q1/6886 ,  C12Q1/6883 ,  A61K39/395 ,  A61K47/68

Abstract: The invention generally relates to methods and compositions for the prediction of therapeutic efficacy of cancer treatments and the prognosis of cancer. The invention discloses markers that are associated with favorable and unfavorable outcomes, respectively, in certain cancer treatments and are useful as prognostic markers for cancer. Methods involving these markers are disclosed for predicting cancer therapy benefit and prognosing clinical outcome for cancer patients.

公开(公告)号：US12178814B2

公开(公告)日：2024-12-31

申请号：US17441361

申请日：2020-04-02

Applicant: ASTELLAS PHARMA INC.

Inventor： Akihiko Sasaki ,  Ko Tanaka ,  Masakazu Miyazaki ,  Seiji Takae

IPC: A61K31/497 ,  A61K9/16 ,  A61K9/20

Abstract: Provided is a pharmaceutical composition containing 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[(oxan-4-yl)amino]pyrazine-2-carboxamide or a pharmaceutically acceptable salt thereof and a sweetener for reducing the bitterness of gilteritinib, suppressing the decrease in dissolution stability of gilteritinib due to, for example, stress such as heat and/or humidity over time, and having excellent dissolution stability. The pharmaceutical composition contains gilteritinib or a pharmaceutically acceptable salt thereof, a sweetener, and sugars and/or sugar alcohols.

公开(公告)号：US12161628B2

公开(公告)日：2024-12-10

申请号：US17959350

申请日：2022-10-04

Applicant: Medivation Prostate Therapeutics LLC ,  Astellas Pharma Inc.

Inventor： Jacqueline Gibbons ,  Joyce Mordenti ,  Michiel De Vries ,  Walter Krauwinkel ,  Taoufik Ouatas

IPC: A61K31/4166 ,  A61K31/438 ,  A61K31/496 ,  A61K31/515 ,  A61K31/55 ,  A61K45/06 ,  A61P35/00 ,  A61K31/435

Abstract: This disclosure provides a dosage regimen for co-administration of enzalutamide and a strong CYP3A4 inducer.

公开(公告)号：US20240335480A1

公开(公告)日：2024-10-10

申请号：US18579100

申请日：2022-07-14

Applicant: Astellas Pharma Inc. ,  OSAKA UNIVERSITY ,  National Center for Child Health and Development

Inventor： Kenichiro SHIMATANI ,  Hiromu SATO ,  Masao SASAI ,  Yoshiki SAWA ,  Atsuhiro SAITO ,  Shigeru MIYAGAWA

IPC: A61K35/545 ,  A61K35/44 ,  C12N5/071

CPC classification number: A61K35/545 ,  A61K35/44 ,  C12N5/069 ,  C12N2506/02 ,  C12N2513/00

Abstract: An object of the present invention is to provide a pericyte-like cell having high angiogenic potential with a higher cell proliferation ability than a primary pericyte available in the past and high VEGF expression, and a method for producing the same. Provided are a method for producing a VEGF-highly expressing pericyte-like cell, the method including selecting a CD56(−) pericyte-like cell from a population including a pericyte-like cell obtained by inducing differentiation of a pluripotent stem cell; and a VEGF-highly expressing pericyte-like cell produced by the production method.

公开(公告)号：US12097189B1

公开(公告)日：2024-09-24

申请号：US18613281

申请日：2024-03-22

Applicant: ASTELLAS PHARMA INC.

Inventor： Yuuki Takaishi ,  Soichiro Nakamura ,  Yutaka Takahashi ,  Takashi Nishizato ,  Daisuke Murayama ,  Emiko Murayama ,  Kazuhiro Sako

IPC: A61K31/426 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K9/28 ,  A61K47/36

CPC classification number: A61K31/426 ,  A61K9/0004 ,  A61K9/1652 ,  A61K9/2031 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/2072 ,  A61K9/2086 ,  A61K9/2846 ,  A61K9/2866 ,  A61K47/36

Abstract: A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a maximum blood drug concentration (Cmax) when administered in fasted state is 400 ng/ml or less, is disclosed.

公开(公告)号：US12077519B2

公开(公告)日：2024-09-03

申请号：US18521400

申请日：2023-11-28

Applicant: Astellas Pharma Inc. ,  Kotobuki Pharmaceutical Co., Ltd.

Inventor： Hideyuki Watanabe ,  Takashi Kamikubo ,  Akio Kamikawa ,  Takuya Washio ,  Yohei Seki ,  Keiichiro Okuyama ,  Osamu Ikeda ,  Hiroshi Tomiyama ,  Yoshinori Iwai ,  Akihiko Nakamura ,  Kozo Miyasaka

IPC: C07D401/12 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/501 ,  A61K31/519 ,  A61P35/00 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D487/04

CPC classification number: C07D401/12 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/501 ,  A61K31/519 ,  A61P35/00 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D487/04

Abstract: A compound useful as an active ingredient of a pharmaceutical composition for treatment of cancer related to activation of immune cells or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapy is provided.
The present inventors have conducted studies on a compound useful as an active ingredient of a pharmaceutical composition for treatment of cancer related to activation of immune cells or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapy, and confirmed that a heteroaryl carboxamide compound has DGK ξ (DGKzeta) inhibitory effect, leading to completion of the present invention. The heteroaryl carboxamide compound of the present invention has DGK ξ inhibitory effect, and can be used as a therapeutic agent for treatment of cancer related to activation of immune cells or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapy.

公开(公告)号：US20240228616A1

公开(公告)日：2024-07-11

申请号：US18051850

申请日：2022-11-01

Applicant: BioNTech AG ,  Astellas Pharma Inc. ,  TRON-Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz

Inventor： Ugur Sahin ,  Ozlem Türeci ,  Christiane Stadler ,  Julia Holland ,  Hayat Bähr-Mahmud ,  Tim Beissert ,  Laura Kring ,  Fabrice Le Gall ,  Arne Jendretzki ,  Markus Fiedler

IPC: C07K16/28 ,  A61K39/00 ,  C07K16/30

CPC classification number: C07K16/2809 ,  C07K16/28 ,  C07K16/30 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/74

Abstract: The present invention provides binding agents that contain a binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefore for treating cancer.

公开(公告)号：US20240209079A1

公开(公告)日：2024-06-27

申请号：US18423761

申请日：2024-01-26

Applicant: Astellas Pharma Inc.

Inventor： Rita MITNACHT-KRAUS ,  Stefan WÖLL ,  Korden WALTER ,  Özlem TÜRECI ,  Ugur SAHIN

IPC: C07K16/28 ,  A61K47/68 ,  G01N33/574

CPC classification number: C07K16/28 ,  A61K47/6849 ,  G01N33/57492 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34

Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN6 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN6.

公开(公告)号：US20240164691A1

公开(公告)日：2024-05-23

申请号：US18283483

申请日：2022-03-23

Applicant: Astellas Pharma Inc.

Inventor： Makoto OGINO ,  Mitsuhisa SHIMIZU ,  Hideki HASHIMOTO ,  Toshiya KAGAWA

IPC: A61B5/355 ,  A61B5/366 ,  G16H50/20

CPC classification number: A61B5/355 ,  A61B5/366 ,  G16H50/20

Abstract: An electrocardiogram analysis assistance device (10) including: an analysis waveform acquisition unit (11C) that acquires waveform data in an electrocardiogram for analysis; an analysis waveform select and extract unit (11D) that selects and extracts waveform data of a predetermined first period from the waveform data acquired by the analysis waveform acquisition unit (11C) as analysis divided waveform data; an intermediate information acquisition unit (11I) that acquires intermediate information generated in a middle layer of a peak estimation model (13C) and indicating a shape feature of a peak contained in the analysis divided waveform data by inputting the analysis divided waveform data selected and extracted by the analysis waveform select and extract unit (11D) into the peak estimation model (13C); and a classification unit (11J) that classifies a type of the waveform of the electrocardiogram for analysis using the intermediate information acquired by the intermediate information acquisition unit (11I).

公开(公告)号：US20240000783A1

公开(公告)日：2024-01-04

申请号：US18041245

申请日：2021-08-10

Applicant: Pfizer Inc. ,  Astellas Pharma Inc.

Inventor： Lars ANDERS ,  Kimberly Hyunjung KIM ,  Danan LI ,  Elizabeth Anne MCMILLAN ,  Robert Andrew ROLLINS ,  Brendan Ayers VEENEMAN

IPC: A61K31/506 ,  A61K31/4166 ,  A61K45/06 ,  A61P35/00

CPC classification number: A61K31/506 ,  A61K31/4166 ,  A61K45/06 ,  A61P35/00

Abstract: This invention relates to combination therapies comprising a cyclin dependent kinase 4 (CDK4) inhibitor of Formula (I) or a pharmaceutically acceptable salt thereof, and an antiandrogen, optionally in further combination with an additional anti-cancer agent, and associated methods of treatment, pharmaceutical compositions, and uses thereof.